Health Canada approves permission for some doctors and therapists to use magic mushrooms!
The mass de-stigmatization has lots to do with companies that are advocating for access to education on psychedelics and their benefits – such as Delic (DELC). I’m excited to see what they have up their sleeves for 2021, both in their stock prices and company developments.
Delic is a community whose goal is to educate and prepare investors for the psychedelic revolution. Global drug policy is changing, and psilocybin mushrooms and psychedelic therapies are likely next in line for decriminalization, research, and sale.
The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative. We need more companies to follow their lead!
Consider investing in Delic – even if you don’t regularly invest, you can invest for very small amounts – it doesn’t need to be thousands of dollars. Why not put your hat in the ring! Delic is a cool business which has focused on educating the public about psychedelic treatments and psychedelic safety.
P.S. Delic not only has a Canadian ticker (CSE : DELC) but also a U.S. ticker for OTC exchange (OTCQB : DELCF).
“Mass de-stigmatization has lots to do with companies that are advocating for access to education on psychedelics and their benefits.”
Disclaimer: This post is for information and harm reduction purposes only. Note that psilocybin is deemed Schedule I substances under the United Nations 1971 Convention on Psychotropic Substances and are illegal in most countries. The author of this blog does not condone the purchase, possession, sale, or consumption of any illegal substances.